Literature DB >> 9277500

Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat.

A Gulati1, A P Sen, A C Sharma, G Singh.   

Abstract

Diaspirin cross-linked hemoglobin (DCLHb) is a hemoglobin-based therapeutic agent that produces significant cardiovascular effects, possibly due to its actions on vasoactive substances, such as endothelin (ET) and nitric oxide (NO). We have studied the modulation of cardiovascular effects of DCLHb by an NO synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), and an ETA-receptor antagonist, FR-139317, in hemorrhaged rats. Control rats resuscitated with vehicle [Ringer lactate (RL), 4 ml/kg iv] did not show any improvement in O2 consumption, base deficit, systemic hemodynamics, or regional blood flow after hemorrhage, and the rats survived for < 70 min. Administration of DCLHb (400 mg/kg iv) significantly improved O2 consumption, base deficit, systemic hemodynamics, and regional blood circulation after resuscitation, and the rats survived for > 120 min after hemorrhage. Plasma ET-1 and guanosine 3',5'-cyclic monophosphate (cGMP) concentrations increased after hemorrhage. DCLHb produced an increase in ET-1 and decreased cGMP concentrations in plasma. Pretreatment with L-NAME (10 mg/kg iv) or FR-139317 (4 mg/kg iv) attenuated the DCLHb-induced improvement in survival time, base deficit, systemic hemodynamics, and regional blood circulation. L-NAME (10 mg/kg iv) per se did not produce any resuscitative effect; therefore the NO mechanism may not be contributing toward the efficacy of DCLHb in hemorrhaged rats. However, FR-139317 attenuated the efficacy of DCLHb; therefore an increase in plasma ET-1 concentration by DCLHb may be contributing toward the efficacy of DCLHb in hemorrhage. Hemorrhage-induced increase in cGMP levels could be attenuated by L-NAME, but L-NAME was not effective in resuscitation of hemorrhaged rats, indicating a lack of role of NO in resuscitation. It is concluded that the ET mechanism is more important in the beneficial effect of DCLHb than the NO mechanism in hemorrhage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9277500     DOI: 10.1152/ajpheart.1997.273.2.H827

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Hemoglobin-based oxygen carriers in trauma care: scientific rationale for the US multicenter prehosptial trial.

Authors:  Ernest E Moore; Aaron M Cheng; Hunter B Moore; Tomohiko Masuno; Jeffrey L Johnson
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

2.  Ascorbate removes key precursors to oxidative damage by cell-free haemoglobin in vitro and in vivo.

Authors:  Jacqueline Dunne; Alexis Caron; Patrick Menu; Abdu I Alayash; Paul W Buehler; Michael T Wilson; Radu Silaghi-Dumitrescu; Beatrice Faivre; Chris E Cooper
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

3.  Endothelin rather than 20-HETE contributes to loss of pial arteriolar dilation during focal cerebral ischemia with and without polymeric hemoglobin transfusion.

Authors:  Suyi Cao; Liang-Chao Wang; Herman Kwansa; Richard J Roman; David R Harder; Raymond C Koehler
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-03-04       Impact factor: 3.619

4.  DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study.

Authors:  Thoralf Kerner; Olaf Ahlers; Siegfried Veit; Bruno Riou; Michael Saunders; Ulrich Pison
Journal:  Intensive Care Med       Date:  2003-01-23       Impact factor: 17.440

5.  The USA Multicenter Prehosptial Hemoglobin-based Oxygen Carrier Resuscitation Trial: scientific rationale, study design, and results.

Authors:  Ernest E Moore; Jeffrey L Johnson; Frederick A Moore; Hunter B Moore
Journal:  Crit Care Clin       Date:  2009-04       Impact factor: 3.598

6.  Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial.

Authors:  Anil Gulati; Dinesh Jain; Nilesh Radheshyam Agrawal; Prashant Rahate; Rajat Choudhuri; Soumen Das; Deba Prasad Dhibar; Madhav Prabhu; Sameer Haveri; Rohit Agarwal; Manish S Lavhale
Journal:  Adv Ther       Date:  2021-05-10       Impact factor: 3.845

Review 7.  Blood substitutes. Haemoglobin therapeutics in clinical practice.

Authors:  J F Baron
Journal:  Crit Care       Date:  1999-09-28       Impact factor: 9.097

8.  Transfusion of Polynitroxylated Pegylated Hemoglobin Stabilizes Pial Arterial Dilation and Decreases Infarct Volume After Transient Middle Cerebral Artery Occlusion.

Authors:  Suyi Cao; Jian Zhang; Li Ma; Carleton J C Hsia; Raymond C Koehler
Journal:  J Am Heart Assoc       Date:  2017-09-12       Impact factor: 5.501

9.  A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients.

Authors:  Anil Gulati; Rajat Choudhuri; Ajay Gupta; Saurabh Singh; S K Noushad Ali; Gursaran Kaur Sidhu; Parvez David Haque; Prashant Rahate; Aditya R Bothra; Gyan P Singh; Sanjiv Maheshwari; Deepak Jeswani; Sameer Haveri; Apurva Agarwal; Nilesh Radheshyam Agrawal
Journal:  Drugs       Date:  2021-06-01       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.